Jacobs Levy Equity Management
ITOS

Jacobs Levy Equity Management’s iTeos Therapeutics ITOS Stock Holding History

Jacobs Levy Equity Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-557,936
Closed -$3.33M – 1103
2025
Q1 		$3.33M Sell
557,936
-364,198
-39% -$2.67M 0.01% 553
2024
Q4 		$7.08M Buy
922,134
+716,271
+348% +$6.15M 0.03% 360
2024
Q3 		$2.1M Buy
205,863
+29,549
+17% +$451K 0.01% 593
2024
Q2 		$2.62M Sell
176,314
-328,231
-65% -$4.7M 0.01% 561
2024
Q1 		$6.88M Sell
504,545
-30,116
-6% -$328K 0.03% 369
2023
Q4 		$5.85M Buy
534,661
+74,949
+16% +$743K 0.03% 399
2023
Q3 		$5.03M Sell
459,712
-30,668
-6% -$392K 0.03% 377
2023
Q2 		$6.49M Sell
490,380
-24,545
-5% -$350K 0.04% 339
2023
Q1 		$7.01M Buy
514,925
+11,395
+2% +$204K 0.04% 339
2022
Q4 		$9.83M Buy
503,530
+37,205
+8% +$727K 0.07% 282
2022
Q3 		$8.88M Buy
+466,325
New +$10.7M 0.07% 276
2022
Q2 		– Sell
-48,545
Closed -$1.56M – 1041
2022
Q1 		$1.56M Buy
48,545
+2,994
+7% +$109K 0.01% 674
2021
Q4 		$2.12M Buy
+45,551
New +$1.52M 0.01% 609
2021
Q3 		– Sell
-26,205
Closed -$672K – 1083
2021
Q2 		$672K Buy
+26,205
New +$624K ﹤0.01% 815

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management's ITOS Position: Q2 2025 in Review

Jacobs Levy Equity Management sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 557,936 shares — an estimated $3.33M sold.

Jacobs Levy Equity Management first reported a position in ITOS in Q2 2021 and held it in 14 quarters. The position peaked at $9.83M in Q4 2022. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • Jacobs Levy Equity Management reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 557,936 iTeos Therapeutics shares in Q2 2025, an estimated $3.33M.
  • Jacobs Levy Equity Management first reported a position in iTeos Therapeutics in Q2 2021 and held it in 14 quarters.
  • Jacobs Levy Equity Management's iTeos Therapeutics position peaked at $9.83M in Q4 2022.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2025, filed 14 Aug 2025.